Vaccines for Enteric Diseases

16-18 October 2019, CHUV, University of Lausanne, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 17th October 2019

SESSION 5:
IMMUNITY& MECHANISMS

Moderator: Milton Maciel Jr. (NMRC, Silver Spring, Maryland, USA)

09.00-09.20
‘Estimates of protection from natural immunity against enteric infections and etiology-specific diarrhea in a longitudinal birth cohort’

Elizabeth T. Rogawski McQuade, Jie Liu, Aldo A.M. Lima, Gagandeep Kang, Amidou Samie, Rashidul Haque, Estomih R. Mduma, Margaret N. Kosek, Jose Paulo Leite, Ladaporn Bodhidatta, Najeeha Iqbal, Nicola Page, Ireen Kiwelu, Zulfiqar Bhutta, Tahmeed Ahmed, Eric R. Houpt and James A. Platts-Mills
(Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA)

09.20-09.40
‘dmLT Adjuvant: Mechanistic insight from omics analyses and polio vaccination’

Elizabeth Norton
(Tulane University, New Orleans, Louisiana, USA)

09.40-10.00
‘Within-host infection dynamics and immunity to invasive bacterial diseases to inform vaccine design’

Pietro Mastroeni
(University of Cambridge, Cambridge, UK)

10.00-10.20
‘Antibody-mediated selective targeting to gut epithelial aminopeptidase N triggers small intestinal immunity’

Raquel Sanz Garcia1, Shruti Bakshi2,3, Hans Van der Weken1, Ann Depicker2,3, Eric Cox1 and Bert Devriendt1
(1 Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium; 2 Department of Plant Biotechnology and Bioinformatics, Ghent University, Gent, Belgium; 3 VIB Center for Plant Systems Biology, Ghent, Belgium)

10.20-10.40
‘Yeast-secreted monomeric IgA prevents ETEC infection in a piglet model’

Vikram Virdi1,2,3,4, Jorge Palaci3,4, Bram Laukens1,2, Stefan Rykaert1,2, Eric Cox5, Erik Vanderbeke6, Ann Depicker3,4 and Nico Callewaert1,2
(1 Department of Biochemistry and Microbiology, Ghent University, Gent, Belgium; 2 VIB Center for Medical Biotechnology, Gent, Belgium; 3 Department of Plant Biotechnology and Bioinformatics, Ghent University, Gent, Belgium; 4 VIB Center for Plant Systems Biology, Gent, Belgium; 5 Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium; 6 AVEVE Biochem, AVEVE Group, Leuven, Belgium)

10.40-11.20
Coffee Break & Poster Session

SESSION 6:
NOROVIRUS VACCINES

Moderator: Jan Holmgren (University of Gothenburg, Gothenburg, Sweden)

11.20-11.40
‘The economic burden of Norovirus Gastroenteritis in the United States and the potential for a vaccine’
Bruce Y. Lee
(Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Carey Business School, Global Obesity Prevention Center (GOPC), Baltimore, Maryland, USA)

11.40-12.00
‘Norovirus Vaccines Progress Overview’
Nicolas Noulin
(hVIVO Ltd, London, UK)

12.00-12.20
‘Progress on the development of an oral, bivalent norovirus vaccine’

David Taylor
(Vaxart Inc., South San Francisco, California, USA)

12.20-12.40
‘Efficacy of an intramuscular bivalent norovirus gi.1/gii.4 virus-like particle vaccine candidate in healthy us adults’
Taisei Masuda
(Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland)

12.40-13.00
‘Risk of post-infectious functional gastrointestinal disorders and gastroesophageal reflux disease following norovirus outbreaks at a naval recruit training facility’

Kayla M. Jaep1, Kawsar R. Talaat2, Mark S. Riddle3, Ramiro L. Gutierrez1 and Chad K. Porter1
(1 Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Johns Hopkins University, Baltimore, Maryland, USA; 3 Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA)

13.00-13.40
Lunch Break & Poster Session

SESSION 7:
SPECIAL SESSION – CAMPYLOBACTER JEJUNI

Moderator: Shahida Baqar (NIAID/NIH, Bethesda, Maryland, USA)

13.40-14.00
‘Development of a capsule conjugate vaccine against Campylobacter jejuni: Past, present and future’
Frédéric Poly1, Renee M. Laird1,2, Mario A. Monteiro3, Chad Porter1 and Patricia Guerry1
(1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Henry M. Jackson Foundation, Bethesda, Maryland, USA; 3 University of Guelph, Guelph, Ontario, Canada)

14.00-14.20
‘Enhanced immunogenicity and protective efficacy of a Campylobacter jejuni conjugate vaccine coadministered with liposomes containing monophosphoryl lipid A and QS-21 in Aotus nancymaae non-human primates’
Renee M. Laird1,2, Amritha Ramakrishnan3, Nina M. Schumack1,2, Gladys Nunez3, Nereyda Espinoza3, Monica Nieto3, Rosa Castillo3, Jesus Rojas3, Andrea J. McCoy3, Zoltan Beck1,4, Gary R. Matyas4, Carl R. Alving4, Patricia Guerry2 and Frédéric Poly2
(1 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA; 2 Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland, USA; 3 Bacteriology Department, U.S. Naval Medical Research Unit No. 6, Callao, Peru; 4 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

14.20-14.40
Campylobacter jejuni capsule type distribution in low and middle-income countries’
Tegan N. Clarke1,2, Chad Porter1 and Frédéric Poly1
(1 Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Henry M. Jackson Foundation, Bethesda, Maryland, USA)

14.40-15.00
‘A glycoconjugate vaccine to reduce Campylobacter jejuni
Harald Nothaft1,2 and Christine M. Szymanski1,2,3
(1 VaxAlta Inc., Edmonton, Canada; 2 University of Alberta, Department of Medical Microbiology and Immunology, Edmonton, Canada; 3 University of Georgia, Department of Microbiology and Complex Carbohydrate Research Center, Athens, Georgia, USA)

15.00-15.20
‘Development of a multivalent, multipathogen conjugate vaccine platform for protection against three major enteric pathogens Campylobacter jejuni, Enterotoxigenic Escherichia coli and Shigella
Renee M. Laird1,2, Milton Maciel Jr.1,2, Steven T. Poole1,2, Michael G. Prouty2, Stephen J. Savarino2, Mario A. Monteiro3, Patricia Guerry2 and Frédéric Poly2
(1 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA; 2 Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland, USA; 3 Department of Chemistry, University of Guelph, Guelph, Ontario, Canada)

15.20-15.40
Tea Break & Posters Session

SESSION 8:
SHIGELLA

Moderators: Armelle Phalipon (Pasteur Institute, Paris, France) and Daniel Cohen (Tel Aviv University, Tel Aviv, Israel)

15.40-16.00
‘Immunoprophylactic efficacy of hyperimmune bovine colostrum (HBC) for shigellosis in rhesus macaques
Dilara Islam1, Nattaya Ruamsap1, Rawiwan Imerbsin1, Jerry Kanellos2, Brett E. Swierczewski3, Robert W. Kaminski3 and John M. Crawford1
(1 Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand; 2 Immuron, Blackburn, Australia; 3 Walter Reed Army Institute of Research (WRAIR), Silver Spring, Maryland, USA)

16.00-16.20
‘An adjuvanted approach to oral vaccination against shigellosis using a killed whole cell vaccine’

Tarun Sharma1, Neeraj Joshi1, Ashwani Kumar Mandyal1, Nidhi Shukla1, Shushruta Bhunia1, Anoop Kumar1, Khalid Ali Syed1, Hemanta Koley2, Shanta Dutta2 and Davinder Gill1
(1 MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. New Delhi, India; 2 NICED, National Institute of Cholera and Enteric Disease, Kolkata, India)

16.20-16.40
‘Estimating a threshold level of serum IgG anti-S. sonnei LPS associated with protection against S. sonnei shigellosis’
Daniel Cohen1, Shiri Meron-Sudai1, Anya Bialik1, Valeria Asato1, Sophy Goren1, Ortal Ariel-Cohen1, Arava Reizis1, Amit Hochberg2 and Shai Ashkenazi3
(1 School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, 2 Hillel Yaffe Medical Center, 3 Adelson School of Medicine, Ariel University, and Schneider Children's Medical Center, Israel)

16.40-17.00
‘GMP manufacture, characterization and clinical evaluation of Shigella flexneri 2a detoxified artificial invaplex’
K.A. Clarkson1, R. Gutierrez2, K.R. Turbyfill1, K. Detizio2, A.R. Vortherms1, A. Lynen2, B. Barnard1, H. Weerts1, C. K. Porter2, N. Maier3, R. Erdem3, A. L. Bourgeois3 and R.W. Kaminski1
(1 Subunit Enteric Vaccines and Immunology, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 2 Naval Medical Research Center, Silver Spring, Maryland, USA; 3 PATH, Washington DC, USA)

17.00-17.20
‘Shigella vaccine based on GMMA-technology: Inducing high level, persistent and boostable antibody responses in human populations’

L.B. Martin, A.G.W. Ndiaye, A. Podda and A. Saul
(GSK Vaccines Institute for Global Health, Siena, Italy)

17.20-17.40
‘Development of a Shigella multivalent bioconjugate vaccine: Toward a phase 1/2 in Kenyan infants’
Cristina Alaimo1, Patricia Martin1, Dominique Sirena1, Mainga Hamaluba2, Josphat Kosgei3, Robert W. Kaminski4 and Veronica Gambillara1
(1 LimmaTech Biologics AG, Schlieren, Switzerland; 2 KEMRI-CGMRC, Kilifi, Kenya; 3 KEMRI-USAMRD-K, Kericho, Kenya; 4 Walter Reed Army Institute of Research, SEVI, Silver Spring, Maryland, USA)

17.40-17.50
Session Discussion

 

VED 2019 Delegates

Login details will be supplied after you have registered for the event.


VED 2019 Sponsors

  • Sanofi Pasteur
  • Vaccine Research Center
  • PATH
  • NatureGeneTherapy.com
  • Vaxart
  • Eveliqure
  • Aldevron
  • Vismederi
  • BioVAXX
  • hVIVO
  • Matrivax
  • Scandinavian Biopharma
  • LimmaTech Biologics
  • DNAvaccine.com
  • Takeda

VED 2019 Downloads

VED 2019 Leaflet

VED 2019 Mailing List

Name
E-mail Address
What is 3+2-1?